Onkologie. 2021:15(4):179-181 | DOI: 10.36290/xon.2021.035
Case report of a patient with metastatic melanoma treated with several lines of systemic treatment
- Dermatovenerologická klinika 1. LF UK a VFN, Praha
This case report of a patient with metastatic, BRAF V600 mutated melanoma represents an example of the sequential therapy. The patient was treated with immunotherapy (with pembrolizumab and ipilimumab) in combination with intralesional therapy, afterwards with combinational chemotherapy and subsequently with two combinations of targeted drugs (dabrafenib plus trametinib, encorafenib plus binimetinib). A review of clinical trials showing high efficacy of the administered drugs is discussed. Current options of systemic anticancer therapy allow to conduct sequential therapy of metastatic melanoma with significant prolongation of progression free survival and with improvement of quality of life.
Keywords: metastatic melanoma, immunotherapy, targeted therapy, sequential therapy.
Published: September 1, 2021 Show citation
References
- Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015; 372(21): 2018-28.
Go to original source... 
Go to PubMed... - Krajsová I, Bauer J. Melanom - imunoterapie a cílená léčba. 1. vydání. Praha: Maxdorf, 2017: 382 s.
- Robert C, Grob JJ, Stroyakovskiy D, et al. Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma. N Engl J Med. 2019; 381(7): 626-636. Go to original source... Go to PubMed...
- Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017; 18(7): 863-873. Go to original source... Go to PubMed...
- Dummer R, Ascierto PA, Gogas HJ, et al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018; 19(5): 603-615. Go to original source... Go to PubMed...